AU2021226994A1 - New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them - Google Patents

New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
AU2021226994A1
AU2021226994A1 AU2021226994A AU2021226994A AU2021226994A1 AU 2021226994 A1 AU2021226994 A1 AU 2021226994A1 AU 2021226994 A AU2021226994 A AU 2021226994A AU 2021226994 A AU2021226994 A AU 2021226994A AU 2021226994 A1 AU2021226994 A1 AU 2021226994A1
Authority
AU
Australia
Prior art keywords
methyl
ethyl
dioxo
ppm
general procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021226994A
Other languages
English (en)
Inventor
Sylvie BERGER
Didier Durand
Valérie DUVIVIER
Márió GYURIS
Árpád KISS
Zoltán MADARÁSZ
Virginie MARTINY
Mark MOLNÁR
Miklós NYERGES
Monika RUDASOVÁ
Klaus Seedorf
Attila SÁPI
Isabelle THERET
Cédric VINSON
Csaba WÉBER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2021226994A1 publication Critical patent/AU2021226994A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2021226994A 2020-02-28 2021-02-26 New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them Pending AU2021226994A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305207.1 2020-02-28
EP20305207 2020-02-28
PCT/EP2021/054780 WO2021170774A1 (en) 2020-02-28 2021-02-26 New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
AU2021226994A1 true AU2021226994A1 (en) 2022-09-08

Family

ID=70977485

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021226994A Pending AU2021226994A1 (en) 2020-02-28 2021-02-26 New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them

Country Status (12)

Country Link
US (1) US20230097678A1 (https=)
EP (1) EP4110776A1 (https=)
JP (1) JP7757298B2 (https=)
KR (1) KR20220148851A (https=)
CN (1) CN115151538B (https=)
AR (1) AR121435A1 (https=)
AU (1) AU2021226994A1 (https=)
BR (1) BR112022016286A2 (https=)
IL (1) IL295595B1 (https=)
MX (1) MX2022010673A (https=)
TW (1) TWI891735B (https=)
WO (1) WO2021170774A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014680A (es) 2019-05-31 2022-04-06 Ube Corp Derivado de benzotriazol.
CN114028374A (zh) * 2021-12-01 2022-02-11 江苏省人民医院（南京医科大学第一附属医院） 富马酸二甲酯在制备用于保护胰岛β细胞功能的药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102301867B1 (ko) * 2013-12-18 2021-09-15 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제

Also Published As

Publication number Publication date
TWI891735B (zh) 2025-08-01
US20230097678A1 (en) 2023-03-30
IL295595A (en) 2022-10-01
BR112022016286A2 (pt) 2022-12-13
AR121435A1 (es) 2022-06-08
CN115151538B (zh) 2026-02-27
CA3170840A1 (en) 2021-09-02
KR20220148851A (ko) 2022-11-07
IL295595B1 (en) 2026-01-01
JP7757298B2 (ja) 2025-10-21
CN115151538A (zh) 2022-10-04
JP2023515572A (ja) 2023-04-13
TW202144367A (zh) 2021-12-01
EP4110776A1 (en) 2023-01-04
WO2021170774A1 (en) 2021-09-02
MX2022010673A (es) 2022-09-23

Similar Documents

Publication Publication Date Title
AU2019289788B2 (en) Pyridinyl and pyrazinyl-(aza)indolsulfonamides
US10081625B2 (en) 5-methyl-1,2,4-oxadiazol-3-yl compounds
EP2603513B1 (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator
EP3983384B1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
TW201121978A (en) Substituted para-biphenyloxymethyl dihydro oxazolopyrimidinones, preparation and use thereof
WO2019154047A1 (zh) 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
KR20230069915A (ko) 신규 화합물
RS62597B1 (sr) Jedinjenje pirazol-oksazolidinona protiv virusa hepatitisa b
AU2021226994A1 (en) New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them
Vaz et al. Synthesis and biological evaluation of 4-hydroxy-methylpiperidinyl-N-benzyl-acylarylhydrazone hybrids designed as novel multifunctional drug candidates for Alzheimer’s disease
CA3170840C (en) Macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them
EA050508B1 (ru) Новые макроциклические соединения, способ их получения и содержащие их фармацевтические композиции
CN115557965B (zh) 双重靶向降解雌激素受体α和芳构化酶的PROTACs化合物及其应用
Tian et al. Design of stapled oxyntomodulin analogs containing functionalized biphenyl cross-linkers
Xu et al. Design, synthesis and biological evaluation of selective histone deacetylase 6 (HDAC6) inhibitors bearing benzoindazole or pyrazoloindazole scaffold as surface recognition motif
HK40078242A (en) New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them
JP5546463B2 (ja) キノロン化合物を含む薬剤
US20230310376A1 (en) Prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis
CZ216895A3 (en) Novel derivatives of 3-hydroxyanthranilic acid, process and intermediates of their preparation, novel pharmaceutical preparations and their use
CA3256688A1 (en) BENZOTRIAZOLE COMPOUND
CN109134492B (zh) 一种噻吩并嘧啶酮类化合物或其药学上可接受的盐及其制备方法和应用
Abed Structure-activity relationships of small molecule direct inhibitors of Keap1-Nrf2 interaction
CN110869375A (zh) 2-氧代-1-咪唑烷基咪唑并噻二唑衍生物
HK1182701A (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator